Pivotal Response Treatment Package for Young Children With Autism

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is a research study examining the effectiveness of a pivotal response treatment package (PRT-P) in targeting language skills in young children with autism.

Official Title

Pivotal Response Treatment Package for Young Children With Autism

Eligibility Criteria

Ages Eligible for Study: 2 Years to 5 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of Autism Spectrum Disorder (ASD) based on Autism Diagnostic Interview- Revised (ADI-R), Autism Diagnostic Observation Schedule (ADOS-2), and expert clinical opinion - Males and females in good medical health between 2.0 and 5.11 years - Ability to participate in the testing procedures to the extent that valid standard scores can be obtained - Language delay as measured by the Preschool Language Scale: Standard score at least 1 Standard Deviation below average for expressive language ability - Stable treatment, speech therapy, school placement, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation - No more than 60 minutes of individual 1:1 speech therapy per week - Availability of at least one parent who can consistently participate in parent training and research measures - Parents intend on continuing Pivotal Response Treatment Package (PRT-P) for a minimum of 12 weeks - Parents must be 18 years of age or older
Exclusion Criteria:
  1. - Current or lifetime diagnosis of severe psychiatric disorder, such as bipolar disorder - Receiving in-home Applied Behavior Analysis (ABA) of 10 hours or more - A genetic abnormality, such as Fragile X - Presence of active medical problem, such as unstable seizure disorder or heart disease - Previous adequate PRT trial - Participants living more than 50 miles from Stanford University - At least one room of the house must be available to be dedicated to treatment during session times - There must be no serious health and safety risks present in the home environment - The research team has the right to refuse to perform sessions in-home even if the criteria above are met


Antonio Hardan, M.D.
Antonio Hardan, M.D.
Professor of Psychiatry and Behavioral Sciences

Contact us to find out if this trial is right for you.


Rachel Schuck, BA